
Centene (CNC) Stock Forecast & Price Target
Centene (CNC) Analyst Ratings
Bulls say
Centene has demonstrated a solid financial foundation, highlighted by a year-over-year improvement in its Medicaid Health Benefit Ratio (HBR) to 93.4%, indicating effective cost management and operational efficiency. The company's expansion in membership within 3.5+ Star plans to 60% enhances its competitive positioning and revenue potential, while a composite rate improvement expectation of approximately 5.5% signifies positive revenue momentum. Additionally, the firm's Medicare and Prescription Drug Plan (PDP) memberships exceeded expectations, further indicating strong market demand and operational performance.
Bears say
Centene's management anticipates a significant decrease in its portfolio allocation to low-cost Silver positions, dropping from 55% in 2025 to 42% in 2026, which may adversely affect revenue stability in the coming years. Additionally, the company has indicated a pre-tax earnings impact of approximately $2.4 billion for fiscal year 2025, driven by risk adjustment revisions that are projected to be $1.8 billion to $2.75 billion lower than prior estimates. Concerns regarding the deterioration of Marketplace risk scores and ongoing pressures on Medicaid margins further exacerbate the negative outlook for Centene’s financial performance.
This aggregate rating is based on analysts' research of Centene and is not a guaranteed prediction by Public.com or investment advice.
Centene (CNC) Analyst Forecast & Price Prediction
Start investing in Centene (CNC)
Order type
Buy in
Order amount
Est. shares
0 shares